Impact News +++ Perma-Fix Awarded $24 Million Contract for Demolition and Disposal Project at Lawrence Livermore... (GlobeNewswire EN) +++ PERMA-FIX Aktie +10,99%

KODIAK SCIENCES Aktie

>KODIAK SCIENCES Aktienkurs

29.96 EUR +52.2% (TradegateBSX)

Ask: 30.2 EUR / 90 Stück

Bid: 29.22 EUR / 90 Stück

Tagesumsatz: 521 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>KODIAK SCIENCES Performance

1 Woche: +2,1%

1 Monat: -18,0%

3 Monate: -15,9%

6 Monate: +41,4%

1 Jahr: +559,3%

laufendes Jahr: -21,4%

>KODIAK SCIENCES Aktie

Name:

KODIAK SCIENCES DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US50015M1099 / A2N6P0

Symbol/ Ticker:

K27 (Frankfurt) / KOD (NASDAQ)

Kürzel:

FRA:K27, ETR:K27, K27:GR, NASDAQ:KOD

Index:

Webseite:

https://kodiak.com/

Profil:

Kodiak Sciences Inc. is a biopharmaceutical company focused on developing innovative therapies to treat retinal diseases. Leveraging its proprietary Antibody Biopolymer Conjugate (ABC) platform, Kodia..
>Volltext..

Marktkapitalisierung:

1169.86 Mio. EUR

Unternehmenswert:

1246.75 Mio. EUR

Umsatz:

EBITDA:

-167.78 Mio. EUR

Nettogewinn:

-187.26 Mio. EUR

Gewinn je Aktie:

-3.55 EUR

Schulden:

139.76 Mio. EUR

Liquide Mittel:

62.07 Mio. EUR

Operativer Cashflow:

-109.17 Mio. EUR

Bargeldquote:

1.7

Umsatzwachstum:

Gewinnwachstum:

-7.62%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

KODIAK SCIENCES

Letzte Datenerhebung:

26.03.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 61.05 Mio. St.

Frei handelbar: 92.86%

Leerverk. Aktien: 12.97%

Rückkaufquote: -0.11%

Mitarbeiter: 109

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 55.95%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 51.37

PEG-Ratio: -0.42

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -73.58%

Eigenkaprendite: -207.92%

>Peer Group

Gesundheit, Antikörper- Behandlung

>KODIAK SCIENCES Chart & Kurs - NASDAQ

>KODIAK SCIENCES News

26.03.26 - 13:30	Jefferies Financial, MillerKnoll dip premarket; Kodiak Sciences surges (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.03.26 - 12:18	Kodiak Sciences: Aktie legt nach positiven Studienergebnissen kräftig zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.03.26 - 11:03	Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham (PR Newswire)
	Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of......

23.02.26 - 20:12	Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy (Fool)
	Focused on retinal disease therapeutics, this clinical-stage biotech advances drug candidates for vision-threatening conditions....

19.02.26 - 23:48	Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead (Fool)
	Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology....

06.02.26 - 19:00	KOD Stock Up 24% in 3 Months: Here′s What You Need to Know (Zacks)
	Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence....

04.02.26 - 13:03	Final APEX Phase 1b Clinical Results for Kodiak′s KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 (PR Newswire)
	PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis......

08.01.26 - 02:21	Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
	PALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th......

20.12.25 - 03:01	Insiderhandel: Aufsichtsrat kauft Aktien von Kodiak Sciences im Wert von 60000008 USD (Insiderkauf)
	Baker Bros. Advisors Lp - Aufsichtsrat - Tag der Transaktion: 2025-12-18...

19.12.25 - 02:30	Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters′ Option to Purchase Additional Shares (PR Newswire)
	PALO ALTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced......

17.12.25 - 08:46	Kodiak Sciences prices upsized $160M stock offering at $23.00 per share (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

17.12.25 - 04:57	Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire)
	PALO ALTO, Calif., Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the pricing of an upsized underwritten public......

15.12.25 - 22:36	Kapitalerhöhung belastet Aktie von Kodiak Sciences (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

15.12.25 - 22:12	Kodiak Sciences launches public offering of 6 mln shares (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.12.25 - 22:06	Kodiak Sciences Announces Proposed Public Offering of Common Stock (PR Newswire)
	PALO ALTO, Calif., Dec. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that it has commenced an underwritten public......

13.11.25 - 22:06	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results (PR Newswire)
	PALO ALTO, Calif., Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025. "Kodiak Sciences has entered a period of strong, sustained momentum driven by compelling......

12.11.25 - 23:51	Kodiak Sciences to Present at Upcoming Investor Conferences (PR Newswire)
	PALO ALTO, Calif., Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that Victor Perlroth, M.D., Chief Executive......

12.09.25 - 19:00	Why Is Kodiak Sciences (KOD) Down 1.2% Since Last Earnings Report? (Zacks)
	Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

19.08.25 - 20:21	Kodiak Sciences to Present at American Chemical Society Fall 2025 (PR Newswire)
	PALO ALTO, Calif., Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present the Company's......

13.08.25 - 23:00	Kodiak Sciences Beats Q2 Loss Estimates (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: So wertlos ist keiner, daß er nicht wenigstens als schlechtes Beispiel herhalten könnte. - Markus M. Ronner

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram